<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613168</url>
  </required_header>
  <id_info>
    <org_study_id>BTC-HER2</org_study_id>
    <nct_id>NCT03613168</nct_id>
  </id_info>
  <brief_title>Trastuzumab in HER2-positive Biliary Tract Cancer</brief_title>
  <acronym>BILHER</acronym>
  <official_title>The Pilot Study of Trastuzumab in Combination With Gemcitabine Plus Cisplatin for HER2-positive Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhoon Yoo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer.&#xD;
      The recent study showed that HER2 overexpression or amplification is noted about 5-15% of&#xD;
      total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and&#xD;
      safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">January 4, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Best response according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between the initiation of chemotherapy and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between the initiation of chemotherapy and any cause of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <condition>HER-2 Gene Amplification</condition>
  <arm_group>
    <arm_group_label>Trastuzumab plus Gem/Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab plus gemcitabine/cisplatin</description>
    <arm_group_label>Trastuzumab plus Gem/Cis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject with disease that is not amendable to a curative treatment approach or&#xD;
             locally advanced or metastatic or unresectable CCC with histological diagnosis&#xD;
&#xD;
          2. At least one measurable(per RECIST 1.1) lesion&#xD;
&#xD;
          3. Primary or metastatic tumor with HER2 positive defined on IHC2+, FISH+ or IHC3+&#xD;
&#xD;
          4. ECOG Performance status 0 or 1&#xD;
&#xD;
          5. At least 3 months for life expectancy Common inclusion criteria&#xD;
&#xD;
          6. Men or women over 19 years at time of signing ICF&#xD;
&#xD;
          7. Signed Informed Consent Form&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          8. Received prior chemotherapy for advanced/metastatic disease (the adjuvant/neoadjuvant&#xD;
             chemotherapy completed at least 6 months before enrolled will be accepted)&#xD;
&#xD;
          9. Not recovery from toxicities related to any prior treatments excluding alopecia (eg,&#xD;
             neurological toxicity to ≥ Grade 2)&#xD;
&#xD;
         10. History of malignancy other than CCC within 5 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death, such as&#xD;
             carcinoma in situ or thyroid papillary carcinoma Hematology, chemistry or organ&#xD;
             function&#xD;
&#xD;
         11. ANC &lt; 1.5 × 109/L, or Platelet &lt; 100 × 109/L&#xD;
&#xD;
         12. Total bilirubin &gt; 1.5 × ULN; or AST/ ALT &gt; 2.5 × ULN (or if the tumor has expanded&#xD;
             into the liver, &gt; 5 × ULN); or, alkaline phosphatase &gt; 2.5 × ULN (or &gt; 5 × if the&#xD;
             tumor has expanded into the liver, or &gt; 10 × ULN if the tumor has expanded into the&#xD;
             brain without liver,); or albumin &lt; 2.5 g/dL&#xD;
&#xD;
         13. Creatinine clearance &lt; 60 mL/min(calculated using the Cockcroft-Gault formula) Other&#xD;
             exclusion criteria related to IP&#xD;
&#xD;
         14. History of proved congestive heart failure; angina with medication; evidence of&#xD;
             transmural myocardial infarction on ECG; uncontrolled hypertension(systolic&gt; 180 mmHg&#xD;
             or diastolic&gt; 100 mmHg); clinically significant heart valve disease; uncontrolled&#xD;
             arrhythmia&#xD;
&#xD;
         15. LVEF &lt; 50% (calculated by cardiac sonography or MUGA)&#xD;
&#xD;
         16. Subject with rest dyspnea due to metastatic tumor or other disease or who needs oxygen&#xD;
             therapy&#xD;
&#xD;
         17. Chronic or high-dose corticosteroid treatment&#xD;
&#xD;
         18. Clinically significant Hearing impairment Common exclusion criteria&#xD;
&#xD;
         19. History or evidence of CNS metastases&#xD;
&#xD;
         20. Interstitial pneumonia or pulmonary fibrosis with symptom and exact lesion on chest&#xD;
             X-ray&#xD;
&#xD;
         21. Hearing loss&#xD;
&#xD;
         22. Uncontrolled significant systemic disease (eg, infection or uncontrolled DM)&#xD;
&#xD;
         23. Pregnant or lactating females&#xD;
&#xD;
         24. Sexually active fertile subjects without contraception&#xD;
&#xD;
         25. Treatment with other investigational therapy within 4 weeks prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
         26. Radiotherapy within 4 weeks prior to initiation of study treatment (the rest at least&#xD;
             2 weeks after palliative radiotherapy for bone metastasis and recovery from the&#xD;
             effects of radiation will be accepted.)&#xD;
&#xD;
         27. Major surgery within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
         28. History of HIV and active HBV or HCV&#xD;
&#xD;
         29. Previously identified allergy or hypersensitivity to components of the study treatment&#xD;
             formulations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changhoon Yoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Changhoon Yoo</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

